Shanghai RAAS Blood Products Co Ltd SZSE:002252:
Q3 NET PROFIT DOWN 26.2% Y/Y
Shanghai RAAS Blood Products Q3 Net Profit Down 26.2% Y/Y
Earlier from Shanghai Raas Blood Products Co., Ltd. Class A
- Shanghai RAAS Blood Products: Revenue and profit fell, but cash flow and strategic expansion strengthened future prospects
- Shanghai RAAS Blood Products: Net profit fell 25% in Q1 2025, but strategic acquisitions and buybacks support future growth
- Shanghai RAAS Blood Products: 2024 saw robust profit growth, Haier control, and strategic expansion for Shanghai RAAS
- Shanghai RAAS Blood Products: Revenue and profit rose in Q3 2024 as Haier Group took control and R&D advanced